Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Van Cutsem, Eric; Tabernero, Josep; Lakomý, Radek; Prenen, Hans; Prausová, Jana; Macarulla, Teresa; Ruff, Paul; A. Van Hazel, Guy; Moiseyenko, Vladimir; Ferry, David; McKendrick, Joe; Polikoff, Jonathan; Tellier, Alexia; Castan, R; J. Allegra, Carmen

doi:10.1200/jco.2012.42.8201

Public

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Published in Journal of Clinical Oncology • Sep 4, 2012

Authors:

Eric Van Cutsem

Josep Tabernero

Radek Lakomý

Abstract

PURPOSE: Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor...

Subject

FOLFIRI

Medicine

Aflibercept

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!